Dendreon (DNDN) Inactive 10-Q2010 Q2 Quarterly report

Filed: 3 Aug 10, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. sophomore Avg

New words: abbreviated, abroad, Aetna, afford, Affordable, alliance, artificially, assimilating, assumption, bad, biennial, biosimilar, blood, Blue, broader, broadly, bundled, castrate, castration, chilling, cited, collection, Compendium, contractor, cox, create, created, creating, creation, curve, decide, diagnostic, dose, drop, duration, easy, educating, educational, effort, Emblem, enforce, England, EU, Europe, examiner, expiration, expire, FDAAA, feasibility, fifteen, fill, foregoing, fraud, geographic, gregory, grow, headcount, hesitant, higher, hour, Humana, identification, ill, immunostimulatory, incorrect, incurrence, infusion, innovation, innovator, integrating, Journal, Kaiser, labor, learning, Louisiana, MAC, mandatory, matter, media, medicine, mentioned, merger, Mississippi, mitigate, Mitigation, NCA, NCCN, NCD, NJ, Obama, occupation, organizational, outlined, outweighing, overcome, paradigm, partial, partner, pathway, people, pivotal, practice, precluded, procedure, prove, publish, ramp, recoverable, Red, refundable, region, regional, regular, resistant, rest, revoke, schiffman, science, screening, shelf, shortage, skill, spend, staffing, stringently, summary, team, technical, theNew, theory, thereunto, tight, unaffiliated, unavailable, undergo, undersigned, underwent, uniform, uninterrupted, unique, unproven, USPTO, utilization, whichever, wholesaler, wider, world, worthy

Removed: alleged, alleging, benign, captionedLoh, claiming, cleared, comprised, Conversely, counsel, deadline, defendant, demanding, derivative, detail, enrichment, expensed, fiduciary, hyperplasia, inLoh, insider, investigate, King, mismanagement, modified, neu, November, opposition, opted, prostatic, pursued, remove, restructuring, ruling, Superior, system, unissued, unjust, wrongful

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

DNDN similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of Dendreon Corporation (the “Company”) on Form 10-Q for the quarter ended June 30, 2010, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned officers of the Company certifies, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to such officer’s knowledge:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of the dates and for the periods expressed in the Report.

Date: August 3, 2010


		Name:		/s/ Mitchell H. Gold, M.D.
				Mitchell H. Gold, M.D.
				President and Chief Executive Officer

				/s/Gregory T. Schiffman
				Gregory T. Schiffman
				Senior Vice President,
				Chief Financial Officer and Treasurer
				(Principal Financial Officer)